HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Continuous subcutaneous lisuride infusion in OPCA.

Abstract
Four patients with sporadic olivopontocerebellar atrophy (OPCA) and severe signs of Parkinsonism received continuous subcutaneous lisuride infusion via a small external pump. All 4 patients benefitted from this treatment: 3 showed an overall improvement in motor performance, in 1 patient mainly dysphagia and dysarthria improved. Therapeutic benefit lasted for at least 6 months of follow up. With a daily dose of 1.0 mg subcutaneous lisuride, treatment limitations were reached in the form of dysphagia, probably due to oropharyngeal dystonia. Subcutaneous lisuride infusion should be taken into consideration in OPCA patients with signs of Parkinsonism if oral dopaminergic treatment has failed earlier on.
AuthorsA Heinz, J Wöhrle, L Schöls, P Klotz, W Kuhn, H Przuntek
JournalJournal of neural transmission. General section (J Neural Transm Gen Sect) Vol. 90 Issue 2 Pg. 145-50 ( 1992) Austria
PMID1463593 (Publication Type: Journal Article)
Chemical References
  • Lisuride
Topics
  • Aged
  • Deglutition Disorders (chemically induced)
  • Female
  • Humans
  • Injections, Subcutaneous
  • Lisuride (administration & dosage, adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Olivopontocerebellar Atrophies (drug therapy)
  • Psychoses, Substance-Induced
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: